Etanercept 是一种结合肿瘤坏死因子 (TNF) 的二聚体融合蛋白，作为 TNF 抑制剂。Etanercept 竞争性地抑制 TNF-α 和 TNF-β 与细胞表面 TNF 受体的结合，使肿瘤坏死因子在生物学上失去活性。Etanercept 对风湿性关节炎、幼年特发性关节炎和斑块性银屑病有效。
| 生物活性 |
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis. |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| 体内研究 |
Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score.
|
||||||||
| 分子式 |
C4H6N4O12
|
||||||||
| CAS号 |
185243-69-0
|
||||||||
| 中文名称 |
依那西普
|
||||||||
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||
| 临床试验 |
|
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet